GAS-CHROMATOGRAPHIC METHOD FOR THE DETERMINATION OF VALPROIC ACID IN HUMAN-PLASMA

被引：12

作者：

HERSHEY, AE ^{[1
]}

PATTON, JR ^{[1
]}

DUDLEY, KH ^{[1
]}

机构：

[1] UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,EPILEPSY & ANTICONVULSANT DRUG RES LAB,CHAPEL HILL,NC 27514

来源：

THERAPEUTIC DRUG MONITORING | 1979年 / 1卷 / 02期

关键词：

chromatography; Valproic acid-Gas;

D O I：

10.1097/00007691-197901020-00004

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

A gas chromatographic method has been developed for the routine monitoring of valproic acid (VPA) in human plasma samples. Two compounds, 2-ethylpentanoic acid (EPA) and 2-propylhexanoic acid (PHA), were synthesized and evaluated as internal standards together with cyclohexane carboxylic acid (CHCA), a commonly employed internal standard. Crystalline barium salts of VPA, EPA, and PHA were prepared, which enabled preparation of standard solutions of high accuracy for use in calibration experiments and in daily intra-laboratory quality control tests. The extraction scheme was designed on the basis of the solvent partitioning properties of VPA. Solvent transfers are required in the extraction scheme, but solvent evaporations are not. Studies were made of the performances of EPA, PHA, and CHCA as internal standards in the VPA assay at different lifetimes of the 109f SP-1000 chromatography column. As judged by these studies, EPA or CHCA is a better choice than PHA as an internal standard, provided that certain guidelines are followed in the use of CHCA. © 1979 Raven Press, New York.

引用

页码：217 / 241

页数：25

共 19 条

[1] Simon D., Penry J.K., Sodium di-n-propylacetate (DPA) in the treatment of epilepsy, Epilepsia, 16, pp. 549-573, (1975)
[2] Pinder R.M., Brogden R.N., Speight T.M., Avery G.S., Sodium valproate: A review of its pharmacological properties and therapeutic efficacy in epilepsy, Drugs, 13, pp. 81-123, (1977)
[3] Zagoni P., Avanzini G., Baruzzi A., Canger R., Gerna M., Righetti A., Morselli P.L., Sodium 2-n-propylpentanoate (2-PP) plasma concentrations in epileptic patients, Pharm Weekbl, 112, pp. 300-304, (1977)
[4] Adams D.J., Luders H., Pippenger C., Sodium valproate in the treatment of intractable seizure disorders: A clinical and electroencephalographic study, Neurology, 28, pp. 152-157, (1978)
[5] Meijer J., GLC of anti-epileptic drugs: Techniques used at the 'Instituut voor Epilepsiebestrijding'
[6] determination of dipropylacetate, Methods of Analysis of Antiepileptic Drugs, pp. 198-206, (1973)
[7] Dijkhuis I.C., Vervloet E., Rapid determination of the antiepileptic drug di-n-propylacetic acid in serum, Pharm Weekbl, 109, pp. 1-4, (1974)
[8] Schobben F., Van Der Kleijn E., Determination of sodium di-n-propylacetate in plasma by gas-liquid chromatography, Pharm Weekbl, 109, pp. 30-33, (1974)
[9] Loscher W., Rapid determination of valproate sodium in serum by gas-liquid chromatography, Epilepsia, 18, pp. 225-227, (1977)
[10] Schmidt D., Ferrandes B., Grandjean D., Gugler R., Jakobs C., Johannessen S., Klotz U., Kochen W., Kupferberg H.J., Meijer J., Richens A., Schafer H., Schulz H.U., Win-Dorfer A., Interlaboratory variability of valproic acid determinations, Arzneim Forsch, 27, pp. 1078-1081, (1977)

← 1 2 →